| HOME >> MEDICINE >> TECHNOLOGY |
$
4,240
$
8,705Short-term investments
30,463
38,125Trade receivable
623
607Receivable from collaboration partner
98
65Inventories
768
786Prepaid expenses and other current assets
1,770
1,082Restricted cash
290
290Total current assets
38,252
49,660Property and equipment, net
774
809Restricted cash
120
120Other assets
253
261Total assets
$
39,399
$
50,850Liabilities and Stockholders' DeficitCurrent liabilities:Accounts payable
$ 1,674
$ 1,544Accrued compensation
1,506
1,867Accrued research and development
821
582Other accrued expenses
4,173
3,011Deferred product revenue, net
563
577Deferred collaboration revenue
7,261
7,242Long term obligations—current portion
2,605
2,222Total current liabilities
18,603
17,045Non-current liabilities:Deferred collaboration revenue
30,554
32,359Deferred rent
67
115Long term obligations
44,230
42,622Total non-current liabilities
74,851
75,096Commitments and contingencies Stockholders' deficit:Common stock, $0.001 par value
18
18Additional paidin capital
215,806
215,220Accumulated other comprehensive gain (loss)
11
(2)Accumulated deficit
(269,890)
(256,527)Total stockholders' deficit
(54,055)
(41,291)Total liabilities and stockholders' deficit
$ 39,399
$ 50,850(Note 1) Derived from the audited consolidated financial statements as of December 31, 2010.NeurogesX, Inc.Stephen Ghiglieri
Executive Vice President, COO
| SOURCE NeurogesX, Inc. Copyright©2010 PR Newswire. All rights reserved |